Form 4: Kura Oncology COO's Stock Vesting and Tax-Related Sale

Kura Oncology's Chief Operating Officer, Kathleen Ford, reported the vesting of performance-based restricted stock units and a subsequent sell-to-cover transaction for tax obligations.

Summary

• Kathleen Ford, Chief Operating Officer of Kura Oncology, Inc., acquired 48,900 shares of common stock on November 13, 2025, at a price of $0 per share.
• This acquisition resulted from the vesting of 1/6th of performance-based restricted stock units (PSUs) granted on May 31, 2023.
• The vesting was triggered by the achievement of a specified development milestone on November 13, 2025.
• Following the vesting, Ford disposed of 6,902 shares of common stock on November 14, 2025, at a price of $11.1769 per share.
• This disposition was a 'sell-to-cover' transaction to satisfy tax obligations associated with the PSU vesting.
• After these transactions, Ford beneficially owns 105,373 shares of common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The core event is the vesting of performance-based units, which signifies the achievement of a company development milestone. The subsequent sale is a routine, non-discretionary tax-related transaction, which is neutral.

Positives

• The vesting of performance-based restricted stock units indicates the achievement of a specified development milestone by Kura Oncology, which is a positive operational indicator for the company.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the future transaction dates related to the vesting schedule.

Industry Context

This Form 4 filing details a routine insider transaction involving the vesting of performance-based equity awards and a subsequent tax-related sale. Such transactions are common across the biotechnology and pharmaceutical industries, where executive compensation often includes equity incentives tied to development milestones.

Stakeholder Impact

• Shareholders: The achievement of a development milestone, which triggered the vesting, could be viewed positively as it indicates progress in the company's pipeline or strategic objectives. The sell-to-cover transaction is a routine event and typically has minimal impact on shareholder sentiment.
• Employees: The vesting of performance-based awards reinforces the company's incentive structure and rewards for achieving strategic goals.

Next Steps

• Future vesting events for the remaining portions of the performance-based restricted stock units will occur upon the achievement of additional specified development milestones and their one-year anniversaries, subject to continuous service.

Key Dates

Keywords

Kura Oncology, KURA, Insider Transaction, Form 4, Stock Vesting, Restricted Stock Units, PSUs, Sell-to-Cover, Chief Operating Officer, Kathleen Ford